Clinical Trial Update: Clinical Trial of 13-Valent Pneumococcal Conjugate Vaccine [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating a 13-valent pneumococcal conjugate vaccine is currently recruiting, sponsored by Sinovac Life Sciences.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Disease

Drugs mentioned

• 13-valent pneumococcal conjugate vaccine (13-valent pneumococcal conjugate vaccine)

Snippet

Sponsor: Sinovac Life Sciences Co., Ltd. | Conditions: Pneumococcal Infectious Disease | Phase 3 | Status: RECRUITING